News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
BioSpace News Archive
Browse BioSpace’s published news and press releases by year, month, and day.
133 Results
Year
2005 (24679)
2006 (34770)
2007 (39687)
2008 (39410)
2009 (42118)
2010 (39616)
2011 (38383)
2012 (38416)
2013 (36268)
2014 (39673)
2015 (44433)
2016 (38330)
2017 (37191)
2018 (39124)
2019 (51338)
2020 (57666)
2021 (58724)
2022 (53928)
2023 (42568)
2024 (38486)
2025 (17535)
Month
January (2946)
February (2976)
March (2714)
April (2913)
May (3639)
June (2347)
Day
1 (184)
2 (144)
5 (162)
6 (107)
7 (309)
8 (243)
9 (171)
12 (212)
13 (134)
14 (258)
15 (267)
16 (110)
19 (118)
20 (147)
21 (149)
22 (140)
23 (133)
26 (20)
27 (148)
28 (183)
29 (192)
30 (107)
31 (1)
Year
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Month
January
February
March
April
May
June
Day
1
2
5
6
7
8
9
12
13
14
15
16
19
20
21
22
23
26
27
28
29
30
31
Dennis Sponer
Dennis Sponer serves as fractional general counsel and advisor to several healthcare companies and VC firms through his consultancy,
SRX Advisors
.
Immunology and inflammation
GSK Wins COPD Expansion for Nucala After FDA Delay
The approval tees GSK up to challenge Sanofi and Regeneron, which in September 2024 won the first biologic approval for COPD for their blockbuster antibody Dupixent.
May 23, 2025
·
1 min read
·
Tristan Manalac
Government
Court Halts HHS’ Reduction and Layoff Plans, Arguing a Lack of Authority
In an opinion issued late Thursday night, U.S. District Judge Susan Illston wrote that the president and department agency heads do not have the authority to reorganize the government without Congress’ input.
May 23, 2025
·
2 min read
·
Dan Samorodnitsky
Vaccines
FDA Vaccine Advisors Agree on COVID-19 Vaccine as New Framework Looms as ‘Elephant in the Room’
The advisory committee meeting comes days after the FDA unveiled a new risk-based approval framework for COVID-19 vaccines.
May 23, 2025
·
2 min read
·
Tristan Manalac
Government
Changes to IRA Pill Penalty Conspicuously Absent as Congress Narrowly Passes Trump’s Tax Bill
The “One Big Beautiful Bill Act” includes negotiation exemptions for orphan drugs approved to treat more than one rare disease and has implications for PBMs. Also on Thursday, the White House released its MAHA report with a mission to “make our children healthy again.”
May 23, 2025
·
2 min read
·
Tristan Manalac
Cancer
Merus’ Bispecific Shows ‘Best in Disease’ Profile in Head-and-Neck Cancer Ahead of ASCO
Analysts were effusive about Merus’ new HNSCC data, writing that petosemtamab could “become the standard of care” in the first-line setting for this indication.
May 23, 2025
·
2 min read
·
Tristan Manalac
FDA
‘Make American Healthy Again’ Report Takes Aim at Pharma Lobbying, GLP-1s and Vaccines
The report takes from HHS Secretary Robert F. Kennedy Jr’s playbook, calling out rising autism rates, the vaccine schedule and over medication of children as reasons for chronic diseases.
May 23, 2025
·
4 min read
·
Annalee Armstrong
Press Releases
Tevogen to Update on Robust Portfolio Assets, Business Expansion, Partnerships, Limited Tradable Float, High Insider Ownership and Strong Investor Confidence Ahead of June 23 Annual Meeting
May 23, 2025
·
4 min read
Press Releases
Arcutis’ ZORYVE® (roflumilast) Topical Foam 0.3% Approved by U.S. FDA for the Treatment of Plaque Psoriasis in Adults and Adolescents Ages 12 and Older
May 23, 2025
·
13 min read
Press Releases
Endurance Bio Inc. Announces Selection of T-168 for Neuro-SysMed’s SLEIPNIR Platform Trial in Parkinson’s Disease
May 23, 2025
·
3 min read
1 of 14
Next